BioLife Solutions Dirección
Dirección controles de criterios 2/4
El CEO de BioLife Solutions es Rod de Greef , nombrado en Oct 2023, tiene una permanencia de 2.58 años. compensación anual total es $10.47M, compuesta por 7.3% salario y 92.7% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.68% de las acciones de la empresa, por valor de $7.99M. La antigüedad media del equipo directivo y de la junta directiva es de 2.6 años y 17.5 años, respectivamente.
Información clave
Rod de Greef
Chief Executive Officer (CEO)
US$10.5m
Compensación total
| Porcentaje del salario del CEO | 7.29% |
| Permanencia del CEO | 2.6yrs |
| Participación del CEO | 0.7% |
| Permanencia media de la dirección | 2.6yrs |
| Promedio de permanencia en la Junta Directiva | 17.5yrs |
Actualizaciones recientes de la dirección
Recent updates
BLFS: New Biopreservation Center Will Support Stronger Margins And Future Returns
Analysts have nudged their price target for BioLife Solutions higher to align with a fair value estimate of about US$32.44 per share, up from roughly US$31.30. This adjustment reflects updated assumptions around slightly lower revenue growth, a modestly higher discount rate, stronger profit margins, and a somewhat lower future P/E multiple.BioLife Solutions: Back To Basics Is Getting Traction (Rating Upgrade)
Summary After multiple acquisitions and significant dilution of shareholders, BioLife shed two freezer businesses that it couldn't get going. Focusing mostly on its core biopreservation media business is putting BLFS on much sounder footing, as it generates the highest margins and the company has a competitive advantage. This is already paying off with cash flow steadily increasing. While the shares are not cheap, revenue growth is likely at 20%+ as more client therapies become commercial. Read the full article on Seeking AlphaBioLife Solutions, Inc.'s (NASDAQ:BLFS) P/S Is Still On The Mark Following 25% Share Price Bounce
BioLife Solutions, Inc. ( NASDAQ:BLFS ) shareholders would be excited to see that the share price has had a great...Is BioLife Solutions (NASDAQ:BLFS) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Investors Still Waiting For A Pull Back In BioLife Solutions, Inc. (NASDAQ:BLFS)
When close to half the companies in the Life Sciences industry in the United States have price-to-sales ratios (or...Expanding Cell And Gene Therapy Workflows Will Shape Future Opportunities
Market leadership in cell and gene therapy, combined with expanded high-value product offerings, drives strong revenue and margin growth opportunities.An Intrinsic Calculation For BioLife Solutions, Inc. (NASDAQ:BLFS) Suggests It's 44% Undervalued
Key Insights BioLife Solutions' estimated fair value is US$44.43 based on 2 Stage Free Cash Flow to Equity BioLife...With BioLife Solutions, Inc. (NASDAQ:BLFS) It Looks Like You'll Get What You Pay For
When you see that almost half of the companies in the Life Sciences industry in the United States have price-to-sales...Is BioLife Solutions (NASDAQ:BLFS) Weighed On By Its Debt Load?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...BioLife Solutions, Inc.'s (NASDAQ:BLFS) Shares Climb 27% But Its Business Is Yet to Catch Up
BioLife Solutions, Inc. ( NASDAQ:BLFS ) shares have had a really impressive month, gaining 27% after a shaky period...Is It Too Late To Consider Buying BioLife Solutions, Inc. (NASDAQ:BLFS)?
BioLife Solutions, Inc. ( NASDAQ:BLFS ), might not be a large cap stock, but it saw a significant share price rise of...Analysts Have Lowered Expectations For BioLife Solutions, Inc. (NASDAQ:BLFS) After Its Latest Results
BioLife Solutions, Inc. ( NASDAQ:BLFS ) investors will be delighted, with the company turning in some strong numbers...Is BioLife Solutions (NASDAQ:BLFS) Using Debt Sensibly?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 20% Undervaluation?
Key Insights BioLife Solutions' estimated fair value is US$31.49 based on 2 Stage Free Cash Flow to Equity BioLife...Why BioLife Solutions, Inc. (NASDAQ:BLFS) Could Be Worth Watching
BioLife Solutions, Inc. ( NASDAQ:BLFS ), is not the largest company out there, but it led the NASDAQCM gainers with a...Investors Appear Satisfied With BioLife Solutions, Inc.'s (NASDAQ:BLFS) Prospects As Shares Rocket 28%
BioLife Solutions, Inc. ( NASDAQ:BLFS ) shareholders would be excited to see that the share price has had a great...BioLife Solutions (NASDAQ:BLFS) Has Debt But No Earnings; Should You Worry?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...A Look At The Fair Value Of BioLife Solutions, Inc. (NASDAQ:BLFS)
Key Insights Using the 2 Stage Free Cash Flow to Equity, BioLife Solutions fair value estimate is US$24.10 BioLife...Revenues Not Telling The Story For BioLife Solutions, Inc. (NASDAQ:BLFS) After Shares Rise 25%
BioLife Solutions, Inc. ( NASDAQ:BLFS ) shares have had a really impressive month, gaining 25% after a shaky period...Broker Revenue Forecasts For BioLife Solutions, Inc. (NASDAQ:BLFS) Are Surging Higher
BioLife Solutions, Inc. ( NASDAQ:BLFS ) shareholders will have a reason to smile today, with the analysts making...Should You Investigate BioLife Solutions, Inc. (NASDAQ:BLFS) At US$19.54?
While BioLife Solutions, Inc. ( NASDAQ:BLFS ) might not have the largest market cap around , it received a lot of...Does BioLife Solutions (NASDAQ:BLFS) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$11m |
| Dec 31 2025 | US$10m | US$763k | -US$12m |
| Sep 30 2025 | n/a | n/a | -US$15m |
| Jun 30 2025 | n/a | n/a | -US$16m |
| Mar 31 2025 | n/a | n/a | -US$5m |
| Dec 31 2024 | US$7m | US$744k | -US$9m |
| Sep 30 2024 | n/a | n/a | US$2m |
| Jun 30 2024 | n/a | n/a | -US$13m |
| Mar 31 2024 | n/a | n/a | -US$13m |
| Dec 31 2023 | US$6m | US$199k | -US$12m |
| Sep 30 2023 | n/a | n/a | -US$79m |
| Jun 30 2023 | n/a | n/a | -US$74m |
| Mar 31 2023 | n/a | n/a | -US$141m |
| Dec 31 2022 | US$2m | US$450k | US$388k |
| Sep 30 2022 | n/a | n/a | -US$106m |
| Jun 30 2022 | n/a | n/a | -US$96m |
| Mar 31 2022 | n/a | n/a | -US$15m |
| Dec 31 2021 | US$1m | US$412k | -US$9m |
| Sep 30 2021 | n/a | n/a | US$5m |
| Jun 30 2021 | n/a | n/a | US$4m |
| Mar 31 2021 | n/a | n/a | -US$20m |
| Dec 31 2020 | US$3m | US$391k | US$2m |
| Sep 30 2020 | n/a | n/a | US$7m |
| Jun 30 2020 | n/a | n/a | US$16m |
| Mar 31 2020 | n/a | n/a | US$39m |
| Dec 31 2019 | US$1m | US$403k | -US$2m |
Compensación vs. Mercado: La compensación total de Rod($USD10.47M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD3.79M).
Compensación vs. Ingresos: La compensación de Rod ha aumentado mientras la empresa no es rentable.
CEO
Rod de Greef (65 yo)
Mr. Roderick de Greef, also known as Rod, serves as Director of BioLife Solutions, Inc. since January 03, 2023 and serves as its Chief Executive Officer & Chairman since October 20, 2023. He had been Presi...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Chairman | 2.6yrs | US$10.47m | 0.68% $ 8.0m | |
| Chief Financial Officer | 4.5yrs | US$3.27m | 0.26% $ 3.1m | |
| Chief Technology Officer | 1.5yrs | US$2.15m | 0.099% $ 1.2m | |
| Chairman of Scientific Advisory Board | 6.4yrs | US$3.19m | 0.60% $ 7.0m | |
| Chief Commercial Officer | 1.5yrs | US$1.93m | 0.25% $ 2.9m |
Equipo directivo experimentado: El equipo directivo de BLFS se considera experimentado (2.6 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Chairman | 3.3yrs | US$10.47m | 0.68% $ 8.0m | |
| Chairman of Scientific Advisory Board | no data | US$3.19m | 0.60% $ 7.0m | |
| Member of Scientific Advisory Board | 19.6yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 18.7yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 19.6yrs | sin datos | sin datos | |
| Member of the Scientific Advisory Board | no data | US$284.00k | sin datos | |
| Member of Scientific Advisory Board | 18.7yrs | sin datos | sin datos | |
| Member of the Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Lead Director | 5.1yrs | US$299.17k | 0.055% $ 644.6k | |
| Independent Director | 4.6yrs | US$254.17k | 0.11% $ 1.3m | |
| Member of Scientific Advisory Board | 17.5yrs | sin datos | sin datos | |
| Independent Director | 1.2yrs | US$234.41k | 0.028% $ 332.9k |
Junta con experiencia: Los miembros de la junta directiva de BLFS son experimentados ( 17.5 años antigüedad media).
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/20 13:12 |
| Precio de las acciones al final del día | 2026/05/20 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
BioLife Solutions, Inc. está cubierta por 18 analistas. 10 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Robert Wasserman | Benchmark Company |
| Paul Knight | Brean Capital Historical (Janney Montgomery) |
| George Zavoico | B. Riley Securities, Inc. |